FDA's dated enforcement report D-0723-2026 lists Class II and source status Ongoing for Lupin Pharmaceuticals Inc. PeptideScanner connects the report to reviewed application ANDA214457 through exact openFDA application-number annotations. 1
FDA's source-reported reason is: CGMP deviation: OOS result observed for the Gliding Force functionality test during 12-month long term stability testing. 1
This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. 1
What this source can tell us. PeptideScanner is reporting the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.